45 Percent of All Hospitalized for COVID-19 Pneumonia Will Show Signs of Fibrosis Six Months Later

Medical News: The Lingering Impact of COVID-19 on the Lungs
A groundbreaking new study has shed light on a significant long-term consequence of COVID-19 pneumonia: nearly half of all patients who were hospitalized due to severe COVID-related pneumonia develop signs of lung fibrosis within six months after recovery. This discovery raises concerns about the lasting respiratory complications of the virus, particularly for those who suffered from severe infections.


45 Percent of All Hospitalized for COVID-19 Pneumonia Will Show Signs of Fibrosis Six Months Later

The study, conducted by researchers from the Hospital General Universitario de Castellón in Spain, highlights the radiological and functional impairments observed in patients post-COVID-19. Published in the Open Respiratory Archives, the findings provide crucial insights into the persistence of lung abnormalities and potential risks for developing chronic respiratory conditions.
 
Uncovering the Extent of Lung Damage
COVID-19 has affected millions worldwide, with symptoms ranging from mild infections to severe pneumonia requiring hospitalization. While many patients recover completely, a significant number experience long-term complications, including persistent lung abnormalities.
 
This Medical News report delves into an observational, prospective study that aimed to evaluate how COVID-19 pneumonia evolves over time and whether fibrosis develops in affected patients. The researchers followed 109 adult patients who had been hospitalized for COVID-19 pneumonia and later discharged.
 
Notably, all participants were unvaccinated, ensuring that the study purely assessed the impact of the infection itself without vaccination-related variables.

Six months after hospital discharge, the researchers performed chest computed tomography (CT) scans on all participants. Based on these follow-up scans, they divided the patients into two groups: those with fibrosis-related changes (45% of the patients) and those without fibrosis (55%).
 
Identifying the Risk Factors for Fibrosis
The study found several key factors associated with an increased likelihood of developing fibrosis:
 
-Age: Older patients had a significantly higher risk of post-COVID fibrosis.
 
-Gender: Surprisingly, the study observed a higher prevalence of fibrosis among female patients - a finding that contrasts with previous research.
 
-Comorbidities: Conditions like hypertension and diabetes were common among patients who developed fibrosis.
 
-Severity of Illness: Patients who had more severe initial lung involvement, longer hospital stays, or required intensive oxygen support were at higher risk.
 
-CT Findings at Initial Diagnosis: Certain lung abnormalities seen during the acute phase of COVID-19, such as bronchial dilatation, subpleural curved lines, and parenchymal bands, were predictors of later fibrosis.
 
Key Study Findings: How COVID-19 Affects the Lungs Over Time
The study provided crucial data on how lung abnormalities evolve in post-COVID patients:
 
-Reduction in Acute Damage: Initially widespread ground-glass opacities and lung consolidations - common signs of COVID-19 pneumonia - showed a significant decrease at six months.
 
-Emergence of Fibrotic Changes: Patients with fibrosis displayed persistent parenchymal bands, irregular interfaces, traction bronchiectasis, and architectural distortions - hallmarks of lung scarring.
 
-Lung Function Decline: Among all participants, 54.6% had impaired lung diffusion capacity (DLCO), meaning their lungs were less effective at transferring oxygen to the bloodstream. This was more pronounced in the fibrosis group, where nearly two-thirds of patients had diminished lung function.
 
-Other Pulmonary Function Reductions: Forced vital capacity (FVC) was lower in 28% of patients, while forced expiratory volume (FEV1) declined in 21%.
 
The Bigger Picture: COVID-19 and Long-Term Lung Damage
The findings of this study align with other long-term studies of viral pneumonia, including previous outbreaks such as SARS and MERS. Past research has shown that while some lung abnormalities improve over time, others persist for years or even decades.
 
Compared to SARS-CoV, COVID-19 appears to have a more prolonged impact on lung health. Previous SARS studies found that, at six months, 76% of survivors still had ground-glass opacities, and 71% had a reticular lung pattern. By 15 years after infection, a small percentage (4%) still exhibited fibrotic changes on imaging. Whether post-COVID fibrosis follows a similar pattern remains unknown, underscoring the need for long-term monitoring and intervention.
 
The Importance of Monitoring and Early Intervention
Given that 45% of hospitalized COVID-19 pneumonia survivors develop fibrosis, ongoing surveillance and early treatment strategies are critical. Physicians and healthcare providers should consider follow-up imaging and lung function tests, particularly for high-risk individuals.
 
Potential treatments and interventions could include:
-Pulmonary rehabilitation programs to improve lung function and overall health.
 
-Anti-fibrotic medications that may help slow or reverse lung scarring.
 
-Oxygen therapy for patients experiencing severe breathing difficulties.
 
-Regular CT scans for early detection of worsening fibrosis.
 
Conclusion: What the Future Holds
This study provides a critical understanding of how COVID-19 pneumonia leads to persistent lung damage, reinforcing the need for extended patient follow-up. With 45% of hospitalized patients developing fibrotic lung changes, healthcare systems must prepare to manage long-term respiratory complications in COVID-19 survivors.
 
The study also highlights the importance of preventative measures, including vaccinations and early treatment interventions, to reduce the severity of lung infections. While some lung damage may gradually improve, others could develop permanent respiratory impairment, affecting quality of life and overall health.
 
More research is needed to determine whether these fibrotic changes will continue progressing or stabilize over time. Future studies should also explore treatment options that may mitigate long-term lung damage.
 
The study findings were published in the peer-reviewed journal: Open Respiratory Archives.
https://www.sciencedirect.com/science/article/pii/S2659663625000116
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/regulatory-t-cells-and-cytokines-in-post-covid-lung-damage-and-idiopathic-fibrosis
 
https://www.thailandmedical.news/news/favipiravir-that-was-used-to-treat-covid-19-actually-causes-lung-inflammation-lung-damage-and-lung-fibrosis
 
https://www.thailandmedical.news/news/new-hopes-for-treating-lung-fibrosis
 
https://www.thailandmedical.news/news/alpinia-officinarum-extract-as-a-potential-treatment-for-lung-fibrosis-
 
https://www.thailandmedical.news/articles/coronavirus